Fig 1: Determining the validity of the constructed senescence predictor. A The correlation between the CS predictor and the CS score in 33 cancers. B Survival analysis of high/low-pred-CS groups at the pan-cancer level. C, D The predictive performance of the CS predictor and the CS score at 1, 3, and 5 years at the pan-cancer level. E–I The expression levels of RAD54L, PIK3IP1, and TRIP13 in different cohorts. J, K qRT-PCR results and representative IHC staining images of tumor tissues and para-cancerous tissues